Merrill rates Amgen at neutral

Amgen Inc. was rated at neutral by Merrill Lynch analyst Eric Ende as the company's legal action against Roche continues. Even if the unpredictable litigation were dismissed, Merrill believes the case would be re-filed by Amgen. In separate litigation, the ITC is moving forward, in response to Amgen's complaint, with an investigation of Roche's importation of PEG-EPO into the United States. Shares of the Thousand Oaks, Calif., biotechnology company were down $0.36 or 0.53%, at $67.54 on volume of 6,688,978 shares versus the three-month running average of 10,187,600 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.